I'm on mobile so please forgive any spelling and grammar errors.
This "update" is frustrating. They talk about how this is exciting news yet there isnt really anything new other than the changes to the MRD arm of the AML trial. I don't understand how they could say so much while saying so little. This was essentially an update on MRD with a bunch of fluff thrown in. It's honestly a joke that we waited essentially six plus months for this "news." They don't elaborate on what they are going to do about frank relapse and adjuvant groups of the AML trial and they just reiterate the same data on the one lymphoma patient they have and the fact that they are waiting on non dilutive funding before beginning the pancreatic trial. Things we already know. What about the addition of the hypomethylating agent combined with MT-401? Was that non clinical test they did last year for nothing? What are they planning with it? We were told a few times last year, albeit not via official press release, that this would be a comprehensive review of the company's portfolio to best determine which way to move forward. Comprehensive my ass. We've been saying for a while now that the focus should be on lymphoma and they are just now getting around to acknowledging that. Again, I don't understand how they can so so much while saying so little.
As of their last communications we are still expecting more lymphoma data the first half of this year so we at least have that to look forward to. If it impresses it should be enough to at least keep the share price stable and bring in some outside interest.
Sorry for the rant. I'm still optimistic here but worry the company will continue to fall into their old ways of over promising and under delivering. Id rather them just keep their mouths shut, get the damn data, and present it. I don't want any fluff PRs. They keep hiring crappy IR agencies and their current one, Tiberend Advisors, is a joke too. Hopefully they figure it out because we all know this company should be worth way more than it is currently valued at.
My DD is not a substitute for your DD
